SNDX Q1 2019 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q1 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$379,000+0.0% YoY

Gross Profit

$379,000100.0% margin

Operating Income

-$15M-3907.9% margin

Net Income

-$14M-3773.6% margin

EPS (Diluted)

$-0.53

QoQ Revenue Growth

-0.3%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$99M

Total Liabilities

$31M

Stockholders' Equity

$69M

Cash & Equivalents

$58M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$379,000	$379,000	+0.0%
Gross Profit	$379,000	$379,000	+0.0%
Operating Income	-$15M	-$20M	+25.0%
Net Income	-$14M	-$19M	+26.3%